Hong Kong’s updated limited partnership legislation has passed into law, giving private equity and venture capital managers the option of domiciling their funds in the territory.
CBC Group’s stewardship of I-Mab Biopharma brings an intensely hands-on platform-based approach to a booming China biotech space often characterized by relatively passive strategies
Newlink Group, operator of a platform that helps drivers in China locate the best value gas stations, has raised a RMB900 million ($128 million) Series D round led by China Capital Investment Group. Xiaomi Corporation also participated.
Chinese biotech start-up Harbour BioMed has raised $102.8 million in Series C funding. It comes four months after it closed an extended Series B round of $75 million.
BlueCity Holdings, the VC-backed holding company for Chinese gay dating platform Blued, traded strongly after raising $84.8 million through a NASDSAQ IPO.
Meishubao, China’s leading online art education platform, has raised $40 million in an extended Series C round led by Tencent Holdings.
Kuaidian, a Chinese interactive content provider, has raised close to $100 million in Series C funding led by Sequoia Capital China. Existing investors GGV Capital and Morningside Venture Capital re-upped.
Warburg Pincus will sell an approximately 5.5% interest in Hong Kong-listed IVF services provider Jinxin Fertility for about HK$1.5 billion ($194 million) through a share placement.
CLSA, the international arm of China-based brokerage CITIC Securities, has launched a strategy to offer high net worth clients investment opportunities in late-stage private companies in Asia.
DCM Ventures has raised $880 million across two funds that will continue its early-stage technology strategy, with 70% of the capital earmarked for deployment in China.
Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations
Cutting non-core operations is the standard corporate response to an economic downturn. Companies in Asia must decide whether the long-term benefits of exposure to new technologies outweighs short-term pain
FineEx, a Shanghai-based logistics provider specializing in e-commerce, has raised RMB500 million ($71 million) in a Series D round of funding led by Baidu Capital.
Ucommune, a Chinese co-working space operator that failed to get traction with an attempted New York IPO last year, has been acquired by a US-listed special purpose acquisition company (SPAC) at a valuation of $764.9 million.
Chinese retailer KK Group - formerly known as KK Guan - has raised RMB1 billion ($41.6 million) in funding led by CMC Capital. BA Capital and Ince Capital Partners also participated.
Chinese venture capital firm Unity Ventures - also known as Jiuhe - has reached a first close of $50 million on its debut US dollar-denominated fund. The vehicle has an overall target of $100 million.
Private equity-backed Chinese coffee shop chain Luckin Coffee has confirmed earlier suspicions of large-scale financial fraud in its operations, while a proposal to remove the company’s chairman failed to receive enough shareholder support.
China-based data storage software services provider XSKY has raised a RMB320 million ($45 million) Series D led by China's State Owned Capital Venture Capital Fund.
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
The Rise Fund, TPG’s impact investment business, has purchased solar projects with a combined capacity of 970 megawatts from China-based Trina Solar for approximately $700 million.
Medical devices has become a difficult place to invest but potentially all the more rewarding for those willing to take the plunge. Asia is in a prime position globally
Chinese radiotherapy business Hygeia Healthcare, which counts Warburg Pincus, Boyu Capital, and CITIC Capital among its investors, raised HK$2.22 billion ($286.4 million) in its Hong Kong IPO.
Beijing-based smart parking management solution provider AIpark has raised a RMB300 million ($42 million) Series C round led by Gaorong Capital.